Ads
related to: wet macular degeneration injection treatments- Wet AMD FAQs
Get Answers To Frequently Asked
Questions About Wet AMD
- Clinical Study Results
See The Results of A Clinical Study
To Learn More About This Treatment
- Financial Assistance
Learn About Financial Support
That May Be Available To You
- Download The Amsler Grid
Use This Test To Help Monitor
Your Vision Between Appointments
- Sign Up For More Info
Sign Up Today To Receive More
Resources And Information
- Appointment Tips
Get Tips And Useful Information
To Talk To Your Specialist
- Wet AMD FAQs
Search results
Results From The WOW.Com Content Network
Following the successful clinical trials in LCA, researchers have been developing similar treatments using adeno-associated virus for age-related macular degeneration (AMD). To date, efforts have focused on long-term delivery of VEGF inhibitors to treat the wet form of macular degeneration. Whereas wet AMD is currently treated using frequent ...
In neovascular age-related macular degeneration (nAMD), key intravitreal agents include Adverum Biotechnologies’ ixoberogene soroparvovec (Ixo-vec) and 4D Molecular Therapeutics’ 4D-150. [4] Both use innovative mechanisms to produce anti-VEGF proteins directly within the eye, significantly reducing the need for frequent anti-VEGF injections.
About Wet AMD. Wet age-related macular degeneration (wet AMD) is a leading cause of vision loss and irreversible blindness in people over the age of 50. Wet AMD is an advanced form of condition that develops when abnormal blood vessels grow into the macular retina, leaking blood or fluid, and leading to potentially severe vision loss.
Pegaptanib [2] sodium injection (brand name Macugen) is an anti-angiogenic medicine for the treatment of neovascular (wet) age-related macular degeneration (AMD). [3] It was discovered by NeXstar Pharmaceuticals (which merged with Gilead Sciences in 1999) and licensed in 2000 to EyeTech Pharmaceuticals, now OSI Pharmaceuticals, for late stage development and marketing in the United States.
“Despite new treatments entering the wet AMD market, there remains a need for safe and durable treatments that provide sustained treatment while decreasing the patient’s need for frequent injections,” said Ashkan M. Abbey, M.D., a principal investigator in the LUGANO clinical trial and Director of Clinical Research at Texas Retina Associates.
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment created from the same parent mouse antibody as bevacizumab.It is an anti-angiogenic [16] that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.
Ad
related to: wet macular degeneration injection treatments